What does AI governance mean in healthcare?

What does AI governance actually govern?

As AI moves into more healthcare workflows, healthcare leaders face difficult questions: How do you know an AI capability is ready to use at your organization? And how do you ensure it remains reliable as your organization and the healthcare environment change?

Answering these questions requires a new kind of scrutiny. An AI capability can behave in ways traditional software doesn’t: the same input can produce different outputs, and performance can shift even when no code has changed.

AI performance also depends partly on the conditions in which it’s used. A capability may perform differently when introduced to a new specialty, patient population, geography, or enterprise customer. The data feeding the AI can change. Payer rules can change. New diseases and other shifts in healthcare can introduce situations the AI hasn’t encountered before.

AI governance gives leaders a way to manage that variability. Before a product is released, teams need to decide what good performance looks like, test against those expectations, and set clear thresholds for what can ship. After release, they need to keep watching performance and respond when results warrant another look.

That’s the difference between documenting how an organization intends to use AI responsibly and building governance into how AI is developed, released, and managed.

Why traditional software governance isn’t enough for AI

Healthcare organizations already govern technology through patient safety; software development; and security, regulatory, and contractual controls. While these controls remain essential, AI introduces a different question: Is the capability performing as intended, for the people and conditions in which it’s being used?

Testing whether an AI feature technically works isn’t enough to answer that question. Consider a capability evaluated with data from one set of specialties and patient populations. If it is later introduced to a new specialty or population, its code may be unchanged, but the conditions it encounters are not.

Teams therefore need defined performance criteria before release, clear thresholds for determining readiness, and continued monitoring to identify when changing conditions warrant review.

Traditional controls govern the broader risks of developing and deploying healthcare technology. AI-specific governance adds ongoing scrutiny of how the AI itself performs.

AI governance needs an additional evaluation layer

Putting AI governance into practice starts with a simple idea: decide how you will judge an AI capability before you decide it’s ready.

Before release, that might mean asking:

• How accurate does an AI-generated clinical summary need to be?
• Does it perform consistently across relevant patient populations?
• Is the data used to evaluate it representative of where and how it will be used?
• After deployment, teams need to keep asking whether those answers still hold.

Decide what you’re measuring before you build

Define successful performance based on the capability’s intended use and potential risks. AI performance can vary across different environments, clinical settings, and patient populations. A model performing well in primary care, for example, doesn't necessarily mean it will perform equally well in a specialty or emergency care setting.

Consider evaluation across three areas:

• Validity: Does the feature perform its intended task accurately, reliably, and consistently?
• Bias: Does performance differ across relevant demographic or clinical populations, or does the output introduce unsupported assumptions based on patient characteristics?
• Data quality: Is the data used to develop, validate, and monitor the feature complete, representative, reliable, and appropriate for its intended use?

How teams measure those areas depends on the capability. A predictive model and an AI-generated clinical summary, for example, present different evaluation challenges. Consider the type of capability, level of human oversight, and potential clinical risk when determining the appropriate measures and rigor.

Teams set metrics and minimum performance thresholds before formal evaluation begins. This reduces the risk of choosing or changing a measure because the results look favorable and helps determine whether a capability is ready for release.

Measure performance and establish a release threshold

Once teams know what they’re measuring, they need evidence that the capability meets the standards they set.

Take an AI-powered documentation solution, for example. One question is whether the draft notes it generates are accurate, complete, useful, internally consistent, and grounded in the patient encounter. Clinician and patient-safety experts help define those standards and assess performance across care settings. A calibrated LLM-based evaluation can apply the same standards across a much larger sample, providing additional data to supplement the expert assessment.

But measurement alone isn’t governance. The results need to inform a decision.

Teams establish minimum performance thresholds before formal evaluation. Before a clinical workflow feature becomes generally available, teams review results against those thresholds and other relevant evidence. Required evaluations must be complete, material findings investigated, and applicable performance requirements satisfied before final approval.

That turns an evaluation metric into a release gate. The question shifts from “How did the AI perform?” to “Did it perform well enough to move forward?”

Keep evaluating after deployment

Meeting the minimum performance threshold for release tells you how an AI capability performed at a particular point in time. It doesn’t tell you how it will perform indefinitely.

Teams continue monitoring clinical AI features after deployment to see whether they remain within approved performance ranges as real-world use evolves.

Monitoring also needs to lead to action. A missed threshold or other material concern triggers a documented review. Depending on the issue, teams may conduct additional analysis or expert review, mitigate the issue, increase monitoring, restrict deployment, roll back the capability, or re-evaluate it.

This closes the governance loop: set expectations, measure against them, use the results to make release decisions, and keep checking whether those expectations are being met.

Governance is broader than model performance

AI-specific evaluation is one part of a larger governance system. Healthcare organizations still need patient safety, product development, security, privacy, regulatory, and contractual controls alongside it.

Human oversight is especially important. The level of oversight should reflect what the AI does and the potential impact of an error.

But human oversight doesn’t lower the bar for the AI itself. Requiring a clinician to review an AI-generated output doesn’t remove the need to evaluate its quality. If clinicians routinely have to catch errors or substantially correct the output, the AI has simply shifted more work—and risk—to the people reviewing it.

For an AI documentation tool, clinicians review, edit, and approve AI-generated draft documentation before it becomes part of the medical record. Evaluate separately whether those drafts meet defined performance expectations. Both matter: the human provides oversight, while the governance process holds the AI itself to measurable standards.

Five questions to ask your AI vendor about governance

Healthcare leaders don’t need to see every detail of a vendor’s internal governance process. But they should be able to ask how governance affects real decisions about the AI they’re considering.

1. What AI-specific criteria do you establish before developing and releasing a capability?

Look for criteria tied to the capability’s intended use and risks, not simply a general responsible AI policy.

2. How do you measure validity, bias, and data quality before broad release, and what happens if the capability falls short?

The answer should explain what the vendor measures, whether it sets expectations in advance, and how results inform release decisions.

3. How do you monitor performance after deployment, and what triggers a closer review?

Ask how often the vendor evaluates performance, what it monitors, and what happens when results move outside an acceptable range.

4. How do you account for changes in real-world use?

Ask how the vendor determines whether new specialties, populations, geographies, data, payer rules, or workflows affect performance.

5. Who is accountable for AI governance throughout the product lifecycle, and where do clinicians and other experts fit in?

Look for clear ownership and a defined role for human expertise in evaluation, release decisions, monitoring, and response.

The goal is to understand what the vendor actually measures, decides, monitors, and does as a result.

What it means to be governed by design

The clearest evidence of AI governance isn’t a policy document. It’s the decisions the governance process produces: which measures are set, what evidence is required, when a capability is ready for release, and how teams respond when performance changes.

That’s what governed by design looks like in practice. Governance shapes decisions throughout development and deployment, with defined measures, thresholds, human oversight, and ongoing evaluation providing evidence leaders can examine.

For healthcare organizations evaluating AI partners, those mechanisms offer something concrete to look for. They show how a vendor turns its commitments around responsible AI into decisions that shape the technology clinicians and patients ultimately experience.